Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach

Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach

The RNA-dependent RNA polymerase (RdRp) and 3C-like protease (3CLpro) from SARS-CoV-2 play crucial roles in the viral life cycle and are considered the most promising targets for drug discovery against SARS-CoV-2. In this study, FDA-approved drugs were screened to identify the probable anti-RdRp and...

Full description

Bibliographic Details
Main Authors: Zahra Molavi, Sara Razi, Seyed Amir Mirmotalebisohi, Amirjafar Adibi, Marzieh Sameni, Farshid Karami, Vahid Niazi, Zahra Niknam, Morteza Aliashrafi, Mohammad Taheri, Soudeh Ghafouri-Fard, Shabnam Jeibouei, Soodeh Mahdian, Hakimeh Zali, Mohammad Mehdi Ranjbar, Mohsen Yazdani
Format: Article
Language:English
Published: Elsevier 2021-06-01
Series:Biomedicine & Pharmacotherapy
Subjects:
SARS-CoV-2
COVID-19
Drug repurposing
FDA-approved drugs
RdRp
3CLpro
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332221003292

Internet

http://www.sciencedirect.com/science/article/pii/S0753332221003292

Similar Items